

CORRIGENDUM

Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates

SK Kelley, T Gelzleichter, D Xie, WP Lee, WC Darbonne, F Qureshi, K Kissler, E Oflazoglu and IS Grewal

British Journal of Pharmacology (2007) **150**, 248. doi:10.1038/sj.bjp.0707129

Correction to: *British Journal of Pharmacology* (2006) **148**, 1116–1123. doi:10.1038/sj.bjp.0706828

Since the above publication, the authors have noticed an error in the *x* axis of Figure 4, the labeling should read μl^{-1} . The correct figure and legend is shown below:




Figure 4 Pharmacodynamic response of lymphocyte and mononuclear cell counts to SGN-40 either in cynomolgus monkeys. Blood was analyzed by FACS. Lymphocytes were identified using monoclonal antibody markers recognizing surface-cell CD45 and CD14. Total peripheral blood lymphocytes were identified as CD45⁺/CD14⁻ cells within the light-scatter gate. (a) Effect of SGN-40 on B-lymphocytes as characterized using monoclonal antibodies to CD20 cell-surface marker. (b) Pharmacodynamic response of CD3⁺/CD4⁺ lymphocyte counts to SGN-40 in cynomolgus monkeys. Lymphocyte phenotypes were characterized using monoclonal antibodies to CD3 and CD4 cell-surface markers. (c) Pharmacodynamic response of CD3⁺/CD8⁺ lymphocyte counts to SGN-40 in cynomolgus monkeys. Lymphocyte phenotypes were further characterized using monoclonal antibodies to CD3 and CD8 cell-surface markers. Data represent mean values (\pm s.d.).

The authors would like to apologise for this mistake.